Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fovinaciclib plus Fulvestrant in HR+/HER2- Advanced Breast Cancer
NCT05438810Phase 3Unknown
- Sponsor
- Jinzhou Ahon Pharmaceutical Co., Ltd.
- Start
- Jan 2022
- Primary completion
- Feb 2024
- Countries
- 1
01
Overview
A Phase 3 trial of ongiciclib in Hormone-Receptor-Positive Breast Cancer, sponsored by Jinzhou Ahon Pharmaceutical Co., Ltd.. Status: unknown.
02
Drugs
ongiciclib
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT05438810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05438810.